Role of pancreatic stellate cells in chemoresistance in pancreatic cancer

Frontiers in Physiology

Volumn 5 APR, Issue , 2014, Pages

  McCarroll, Joshua A ^a,b   Naim, Stephanie ^b   Sharbeen, George ^b   Russia, Nelson ^b   Lee, Julia ^b   Kavallaris, Maria ^a,b   Goldstein, David ^b   Phillips, Phoebe A ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chemoresistance; Fibrosis; Hypoxia; Pancreatic cancer; Pancreatic stellate cells; Stroma

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GEMCITABINE; LOSARTAN; PACLITAXEL; RECOMBINANT HYALURONIDASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CELL FUNCTION; CELL HYPOXIA; CELL INTERACTION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; NONHUMAN; PANCREAS CANCER; PANCREATIC STELLATE CELL; REVIEW; STROMA; TUMOR MICROENVIRONMENT;

EID: 84900991814     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00141     Document Type: Review

References (95)

1. Alvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megias, D., Guerra, C., et al. (2013). Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926-933. doi: 10.1038/bjc.2013.415
2. Aoki, H., Ohnishi, H., Hama, K., Ishijima, T., Satoh, Y., Hanatsuka, K., et al. (2006a). Autocrine loop between TGF-beta1 and IL-1beta through Smad3- and ERK-dependent pathways in rat pancreatic stellate cells. Am. J. Physiol. Cell Physiol. 290, C1100-C1108. doi: 10.1152/ajpcell.00465.2005
3. Aoki, H., Ohnishi, H., Hama, K., Shinozaki, S., Kita, H., Yamamoto, H., et al. (2006b). Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. J. Cell. Biochem. 99, 221-228. doi: 10.1002/jcb.20906
4. Apte, M. V., Haber, P. S., Applegate, T. L., Norton, I. D., McCaughan, G. W., Korsten, M. A., et al. (1998). Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 43, 128-133. doi: 10.1136/gut.43.1.128
5. Apte, M. V., Haber, P. S., Darby, S. J., Rodgers, S. C., McCaughan, G. W., Korsten, M. A., et al. (1999). Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 44, 534-541. doi: 10.1136/gut.44.4.534
6. Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., et al. (2004). Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179-187. doi: 10.1097/00006676-200410000-00002
7. Apte, M. V., Pirola, R. C., and Wilson, J. S. (2006). Battle-scarred pancreas: role of alcohol and pancreatic stellate cells in pancreatic fibrosis. J. Gastroenterol. Hepatol. 21(Suppl. 3), S97-S101. doi: 10.1111/j.1440-1746.2006.04587.x
8. Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., et al. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820-5828. doi: 10.1158/0008-5472.can-08-2819
9. Bachem, M. G., Schunemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A., et al. (2005). Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921. doi: 10.1053/j.gastro.2004.12.036
10. Bao, B., Azmi, A. S., Ali, S., Ahmad, A., Li, Y., Banerjee, S., et al. (2012). The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim. Biophys. Acta. 1826, 272-296. doi: 10.1016/j.bbcan.2012.04.008
11. Bardeesy, N., and Depinho, R. A. (2002). Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909. doi: 10.1038/nrc949
12. Bristow, R. G., and Hill, R. P. (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192. doi: 10.1038/nrc2344
13. Buchler, P., Reber, H. A., Lavey, R. S., Tomlinson, J., Buchler, M. W., Friess, H., et al. (2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J. Surg. Res. 120, 295-303. doi: 10.1016/j.jss.2004.02.014
14. Castellanos, J. A., Merchant, N. B., and Nagathihalli, N. S. (2013). Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco. Targets. Ther. 6, 1261-1267. doi: 10.2147/ott.s34670
15. Chan, N., and Bristow, R. G. (2010). "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin. Cancer Res. 16, 4553-4560. doi: 10.1158/1078-0432.ccr-10-0527
16. Chang, Q., Jurisica, I., Do, T., and Hedley, D. W. (2011). Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res. 71, 3110-3120. doi: 10.1158/0008-5472.can-10-4049
17. Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516. doi: 10.1038/ncomms3516
18. Chen, Y., Cairns, R., Papandreou, I., Koong, A., and Denko, N. C. (2009). Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS ONE 4:e7033. doi: 10.1371/journal.pone.0007033
19. Conklin, M. W., and Keely, P. J. (2012). Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh. Migr. 6, 249-260. doi: 10.4161/cam.20567
20. Dong, X., Tang, H., Hess, K. R., Abbruzzese, J. L., and Li, D. (2011). Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer 117, 480-491. doi: 10.1002/cncr.25612
21. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239. doi: 10.1016/j.ccr.2009.01.021
22. Eguchi, D., Ikenaga, N., Ohuchida, K., Kozono, S., Cui, L., Fujiwara, K., et al. (2013). Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor. J. Surg. Res. 181, 225-233. doi: 10.1016/j.jss.2012.06.051
23. Erkan, M., Adler, G., Apte, M. V., Bachem, M. G., Buchholz, M., Detlefsen, S., et al. (2012). StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut. 61, 172-178. doi: 10.1136/gutjnl-2011-301220
24. Erkan, M., Kleeff, J., Esposito, I., Giese, T., Ketterer, K., Buchler, M. W., et al. (2005). Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24, 4421-4432. doi: 10.1038/sj.onc.1208642
25. Erkan, M., Michalski, C. W., Rieder, S., Reiser-Erkan, C., Abiatari, I., Kolb, A., et al. (2008). The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161. doi: 10.1016/j.cgh.2008.05.006
26. Erkan, M., Reiser-Erkan, C., Michalski, C. W., Deucker, S., Sauliunaite, D., Streit, S., et al. (2009). Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11, 497-508. doi: 10.1593/neo.81618
27. Erkan, M., Reiser-Erkan, C., Michalski, C. W., and Kleeff, J. (2010). Tumor microenvironment and progression of pancreatic cancer. Exp. Oncol. 32, 128-131.
28. Evans, A., and Costello, E. (2012). The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front. Physiol. 3:270. doi: 10.3389/fphys.2012.00270
29. Evans, S. M., and Koch, C. J. (2003). Prognostic significance of tumor oxygenation in humans. Cancer Lett. 195, 1-16. doi: 10.1016/S0304-3835(03)00012-0
30. Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., and Tuveson, D. A. (2012). The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266-4276. doi: 10.1158/1078-0432.ccr-11-3114
31. Gao, R., and Brigstock, D. R. (2005). Connective tissue growth factor (CCN2) in rat pancreatic stellate cell function: integrin alpha5beta1 as a novel CCN2 receptor. Gastroenterology 129, 1019-1030. doi: 10.1053/j.gastro.2005.06.067
32. Gao, Z., Wang, X., Wu, K., Zhao, Y., and Hu, G. (2010). Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 10, 186-193. doi: 10.1159/000236012
33. Greijer, A. E., Van Der Groep, P., Kemming, D., Shvarts, A., Semenza, G. L., Meijer, G. A., et al. (2005). Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J. Pathol. 206, 291-304. doi: 10.1002/path.1778
34. Hamada, S., Masamune, A., and Shimosegawa, T. (2013). Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front. Physiol. 4:318. doi: 10.3389/fphys.2013.00318
35. Hidalgo, M. (2010). Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617. doi: 10.1056/NEJMra0901557
36. Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., and Pshevlotsky, E. M. (2013). A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J. Clin. Oncol. 31:4010.
37. Hoffmann, A. C., Mori, R., Vallbohmer, D., Brabender, J., Klein, E., Drebber, U., et al. (2008). High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10, 674-679. doi: 10.1593/neo08292
38. Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., et al. (2008). Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926. doi: 10.1158/0008-5472.can-07-5714
39. Ide, T., Kitajima, Y., Miyoshi, A., Ohtsuka, T., Mitsuno, M., Ohtaka, K., et al. (2007). The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 14, 2600-2607. doi: 10.1245/s10434-007-9435-3
40. Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., et al. (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62, 112-120. doi: 10.1136/gutjnl-2012-302529
41. Jiang, X., Abiatari, I., Kong, B., Erkan, M., De Oliveira, T., Giese, N. A., et al. (2009). Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology 9, 165-172. doi: 10.1159/000178888
42. Ke, Q., and Costa, M. (2006). Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70, 1469-1480. doi: 10.1124/mol.106.027029
43. Kikuta, K., Masamune, A., Watanabe, T., Ariga, H., Itoh, H., Hamada, S., et al. (2010). Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 403, 380-384. doi: 10.1016/j.bbrc.2010.11.040
44. Komar, G., Kauhanen, S., Liukko, K., Seppanen, M., Kajander, S., Ovaska, J., et al. (2009). Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin. Cancer Res. 15, 5511-5517. doi: 10.1158/1078-0432.ccr-09-0414
45. Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., et al. (2000). Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48, 919-922. doi: 10.1016/S0360-3016(00)00803-8
46. Kordes, C., Brookmann, S., Haussinger, D., and Klonowski-Stumpe, H. (2005). Differential and synergistic effects of platelet-derived growth factor-BB and transforming growth factor-beta1 on activated pancreatic stellate cells. Pancreas 31, 156-167. doi: 10.1097/01.mpa.0000168222.05591.a0
47. Kozono, S., Ohuchida, K., Eguchi, D., Ikenaga, N., Fujiwara, K., Cui, L., et al. (2013). Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 73, 2345-2356. doi: 10.1158/0008-5472.can-12-3180
48. Li, J., Wientjes, M. G., and Au, J. L. (2010). Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 12, 223-232. doi: 10.1208/s12248-010-9181-5
49. Masamune, A., Kikuta, K., Watanabe, T., Satoh, K., Hirota, M., and Shimosegawa, T. (2008). Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G709-G717. doi: 10.1152/ajpgi.90356.2008
50. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20, 5197-5206. doi: 10.1093/emboj/20.18.5197
51. Mews, P., Phillips, P., Fahmy, R., Korsten, M., Pirola, R., Wilson, J., et al. (2002). Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut. 50, 535-541. doi: 10.1136/gut.50.4.535
52. Michl, P., and Gress, T. M. (2013). Current concepts and novel targets in advanced pancreatic cancer. Gut. 62, 317-326. doi: 10.1136/gutjnl-2012-303588
53. Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M., Mori, S., Oka, M., et al. (2007). Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 30, 849-855. doi: 10.3892/ijo.30.4.849
54. Miyamoto, H., Murakami, T., Tsuchida, K., Sugino, H., Miyake, H., and Tashiro, S. (2004). Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28, 38-44. doi: 10.1097/00006676-200401000-00006
55. Muerkoster, S., Wegehenkel, K., Arlt, A., Witt, M., Sipos, B., Kruse, M. L., et al. (2004). Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 64, 1331-1337. doi: 10.1158/0008-5472.CAN-03-1860
56. Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., et al. (2010). Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 103, 1644-1648. doi: 10.1038/sj.bjc.6605955
57. Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Takahara, N., Ito, Y., et al. (2013). A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest. New Drugs 31, 1294-1299. doi: 10.1007/s10637-013-9972-5
58. Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., et al. (2013). SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. doi: 10.1136/gutjnl-2013-305559. [Epub ahead of print].
59. Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., et al. (2011). Stromal biology and therapy in pancreatic cancer. Gut. 60, 861-868. doi: 10.1136/gut.2010.226092
60. Ohnishi, N., Miyata, T., Ohnishi, H., Yasuda, H., Tamada, K., Ueda, N., et al. (2003). Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut. 52, 1487-1493. doi: 10.1136/gut.52.10.1487
61. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461. doi: 10.1126/science.1171362
62. Omary, M. B., Lugea, A., Lowe, A. W., and Pandol, S. J. (2007). The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117, 50-59. doi: 10.1172/jci30082
63. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231. doi: 10.1016/j.ccr.2009.01.027
64. Phillips, P. (2012). "Pancreatic stellate cells and fibrosis," in Pancreatic Cancer and Tumor Microenvironment, eds P. J. Grippo and H. G. Munshi (Trivandrum: Transworld Research Network).
65. Phillips, P. A., McCarroll, J. A., Park, S., Wu, M. J., Pirola, R., Korsten, M., et al. (2003a). Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 52, 275-282. doi: 10.1136/gut.52.2.275
66. Phillips, P. A., Wu, M. J., Kumar, R. K., Doherty, E., McCarroll, J. A., Park, S., et al. (2003b). Cell migration: a novel aspect of pancreatic stellate cell biology. Gut. 52, 677-682. doi: 10.1136/gut.52.5.677
67. Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., and Hingorani, S. R. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429. doi: 10.1016/j.ccr.2012.01.007
68. Raimondi, S., Maisonneuve, P., and Lowenfels, A. B. (2009). Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699-708. doi: 10.1038/nrgastro.2009.177
69. Salnikov, A. V., Kusumawidjaja, G., Rausch, V., Bruns, H., Gross, W., Khamidjanov, A., et al. (2009). Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275, 185-193. doi: 10.1016/j.canlet.2008.10.015
70. Schneider, E., Schmid-Kotsas, A., Zhao, J., Weidenbach, H., Schmid, R. M., Menke, A., et al. (2001). Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am. J. Physiol. Cell Physiol. 281, C532-C543.
71. Schneiderhan, W., Diaz, F., Fundel, M., Zhou, S., Siech, M., Hasel, C., et al. (2007). Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J. Cell Sci. 120, 512-519. doi: 10.1242/jcs.03347
72. Schwartz, D. L., Bankson, J. A., Lemos, R. Jr., Lai, S. Y., Thittai, A. K., He, Y., et al. (2010). Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol. Cancer Ther. 9, 2057-2067. doi: 10.1158/1535-7163.mct-09-0768
73. Semenza, G. L., Shimoda, L. A., and Prabhakar, N. R. (2006). Regulation of gene expression by HIF-1. Novartis Found. Symp. 272, 2-8. discussion: 8-14, 33-16. doi: 10.1002/9780470035009.ch2
74. Shek, F. W., Benyon, R. C., Walker, F. M., McCrudden, P. R., Pender, S. L., Williams, E. J., et al. (2002). Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 160, 1787-1798. doi: 10.1016/S0002-9440(10)61125-X
75. Shibaji, T., Nagao, M., Ikeda, N., Kanehiro, H., Hisanaga, M., Ko, S., et al. (2003). Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23, 4721-4727.
76. Spivak-Kroizman, T. R., Hostetter, G., Posner, R., Aziz, M., Hu, C., Demeure, M. J., et al. (2013). Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. 73, 3235-3247. doi: 10.1158/0008-5472.can-11-1433
77. Srinivas, V., Zhang, L. P., Zhu, X. H., and Caro, J. (1999). Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem. Biophys. Res. Commun. 260, 557-561. doi: 10.1006/bbrc.1999.0878
78. Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., et al. (2012). Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 15101-15108. doi: 10.1073/pnas.1213353109
79. Sun, H. C., Qiu, Z. J., Liu, J., Sun, J., Jiang, T., Huang, K. J., et al. (2007). Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 30, 1359-1367. doi: 10.3892/ijo.30.6.1359
80. Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., et al. (2012). Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer Res. 18, 758-770. doi: 10.1158/1078-0432.ccr-11-1980
81. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., and Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234. doi: 10.1038/nrd1984
82. Thompson, C. B., Shepard, H. M., O'Cconnor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., et al. (2010). Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9, 3052-3064. doi: 10.1158/1535-7163.mct-10-0470
83. Tod, J., Jenei, V., Thomas, G., and Fine, D. (2013). Tumor-stromal interactions in pancreatic cancer. Pancreatology 13, 1-7. doi: 10.1016/j.pan.2012.11.311
84. Vincent, A., Herman, J., Schulick, R., Hruban, R. H., and Goggins, M. (2011). Pancreatic cancer. Lancet 378, 607-620. doi: 10.1016/s0140-6736(10)62307-0
85. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703. doi: 10.1056/NEJMoa1304369
86. Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554. doi: 10.1200/jco.2011.36.5742
87. Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., et al. (2008a). Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093. doi: 10.1158/0008-5472.can-07-2477
88. Vonlaufen, A., Phillips, P. A., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., et al. (2008b). Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res. 68, 7707-7710. doi: 10.1158/0008-5472.can-08-1132
89. Vonlaufen, A., Phillips, P. A., Yang, L., Xu, Z., Fiala-Beer, E., Zhang, X., et al. (2010). Isolation of quiescent human pancreatic stellate cells: a promising in vitro tool for studies of human pancreatic stellate cell biology. Pancreatology 10, 434-443. doi: 10.1159/000260900
90. Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., et al. (2011). Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 8, 27-33. doi: 10.1038/nrgastro.2010.188
91. Watanabe, I., Hasebe, T., Sasaki, S., Konishi, M., Inoue, K., Nakagohri, T., et al. (2003). Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome. Pancreas 26, 326-333. doi: 10.1097/00006676-200305000-00003
92. Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., et al. (2013). Recent progress in pancreatic cancer. CA Cancer J. Clin. 63, 318-348. doi: 10.3322/caac.21190
93. Xu, Z., Vonlaufen, A., Phillips, P. A., Fiala-Beer, E., Zhang, X., Yang, L., et al. (2010). Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177, 2585-2596. doi: 10.2353/ajpath.2010.090899
94. Yamada, T., Kuno, A., Masuda, K., Ogawa, K., Sogawa, M., Nakamura, S., et al. (2003). Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J. Pharmacol. Exp. Ther. 307, 17-23. doi: 10.1124/jpet.103.053322
95. Zalatnai, A., and Molnar, J. (2007). Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 21, 339-347.